GLP-3 (RT)

CAS 2381089-83-2 · Metabolic Research

10 MG

$69.00

✔ ORDER NOW · SHIPS TODAY

Bulk Discount

⚠ RESEARCH USE ONLY

This product is sold strictly for in vitro laboratory research use only. Not for human or animal consumption, diagnostic use, or therapeutic application. Purchasers must be qualified researchers or authorized purchasers for a research institution.

CERTIFICATE OF ANALYSIS

Third party tested for: Purity · ID · Quantity

BATCH #2606010456
View All →

View on PubChem→

GLP-3 (RT) Overview

GLP-3 (RT) is a synthetic 39-amino-acid peptide engineered as a triple agonist targeting the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon-like peptide-1 receptor (GLP-1R). Its multi-receptor activity is studied for the way it may model coordinated signaling across three metabolic pathways in a single molecule.

In research models, GLP-3 (RT) has been examined for its role in appetite signaling, gastric-emptying kinetics, insulin secretion pathways, energy expenditure, and hepatic lipid handling.

Reference: Coskun T. et al. (2022), Cell Metabolism, 34(9), 1234-1247.

History

GLP-3 (RT) emerged from research programs exploring polypharmacology at incretin receptors. Building on decades of study of GLP-1 and GIP biology, and the rediscovery of glucagon’s role in energy balance, the molecule was designed to activate all three receptors from a single sequence. Early preclinical work reported in the peer-reviewed literature (2022) described its receptor-binding profile and its use as a tool compound in metabolic research.

Reference: Urva S. et al. (2022), Clinical Pharmacokinetics, 61, 1057-1069.

GLP-3 (RT) Structure

CAS #: 2381089-83-2

Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈

Molecular Weight: 4,731.33 g/mol

PubChem CID: 171390338

Research Findings

GLP-3 (RT) has been studied in preclinical rodent and non-human primate models, as well as early-phase human research settings. Reported findings describe simultaneous activity at three metabolic receptors, coordinated effects on food intake, glucose handling, and energy expenditure, and dose-dependent changes in body composition across published research.

Key Areas of Research:

Appetite signaling: GLP-1R activation and central-nervous-system feeding circuits
Glucose regulation: GIP-mediated insulin secretion in a glucose-dependent manner
Energy expenditure: GCGR-driven hepatic fat oxidation and thermogenesis
Body composition: Fat-mass reduction and lean-mass preservation in animal studies

These converging observations make GLP-3 (RT) a widely-used research tool for studying how multi-receptor peptide agonists coordinate signaling across the incretin, glucagon, and GIP axes.

References: Jastreboff A. M. et al. (2023), NEJM, 389, 514-526; Rosenstock J. et al. (2023), The Lancet, 402(10401), 529-544.

References

Coskun T. et al. (2022). A novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism, 34(9), 1234-1247.
Jastreboff A. M. et al. (2023). Triple-hormone-receptor agonist for the treatment of obesity. New England Journal of Medicine, 389, 514-526.
Rosenstock J. et al. (2023). Efficacy and safety of a novel triple agonist for type 2 diabetes. The Lancet, 402(10401), 529-544.
Urva S. et al. (2022). Pharmacokinetics and pharmacodynamics of the novel triple receptor agonist in healthy participants. Clinical Pharmacokinetics, 61, 1057-1069.
Sanchez-Garrido M. A. et al. (2017). GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia, 60(10), 1851-1861.

Frequently Asked Questions

Everything you need to know about our products and processes.

Each vial contains the exact quantity listed on the label. A 10 mg vial contains 10 mg of lyophilized peptide. Research-grade purity supports accurate dosing for experimental protocols.

Peptides ship as lyophilized powder. Every order includes a complimentary vial of bacteriostatic water for reconstitution. Any additional supplies (syringes, mixing vials, etc.) must be sourced separately by the research institution.

Sealed lyophilized peptide remains stable for approximately 2 years when stored properly. After reconstitution, the solution should be refrigerated and typically retains stability for several weeks depending on temperature and handling conditions.

No. Our products are supplied strictly for in vitro laboratory research. Because these compounds are not authorized for use on humans or animals outside approved research settings, we do not provide usage or dosing instructions.

All peptides are guaranteed to be at least 98% pure, verified by HPLC and mass spectrometry. A Certificate of Analysis is available for every batch.

Keep lyophilized peptides in a cool, dry place away from direct heat and light. Once reconstituted, refrigerate the solution to maintain stability and preserve peptide integrity.